Quick Facts

• Cefalon ER is utilized to manage bacterial infections.
• It assists in addressing conditions such as respiratory tract infections.
• The medication may be included in the treatment of skin and soft tissue infections.
• It also forms part of the regimen for certain urinary tract infections.

---

What Cefalon ER Treats: Main Uses and Benefits

Cefalon ER is a prescription medication indicated for the treatment of a range of infections caused by susceptible bacteria. It contributes to the resolution of lower respiratory tract infections, including certain types of pneumonia, when the infection is linked to specific microorganisms. The medication offers a therapeutic option for managing acute and chronic urinary tract infections. Furthermore, Cefalon ER provides support in addressing skin and soft tissue infections. Its primary role is to mediate against the growth of various strains of Streptococcus and Staphylococcus bacteria, as well as certain Gram-negative bacteria like Escherichia coli and Proteus mirabilis. The clinical utility of this medication is grounded in its established activity against these susceptible pathogens.

Who Must Not Use Cefalon ER

Cefalon ER is contraindicated and must not be used by individuals with a known allergy or severe hypersensitivity reaction to the active ingredient, Cefalexin. This prohibition also extends to patients with a known allergy to any other medication belonging to the cephalosporin class of antibiotics.

---

Restricted or Conditional Eligibility

Use of Cefalon ER requires caution and is restricted for several patient populations as defined by regulatory documents:

• Organ Function: Patients with markedly impaired renal function (kidney disease) need careful clinical consideration. Caution is also advised for those with hepatic impairment (liver disease).
• Allergy History: Individuals with a history of penicillin allergy must be treated with caution due to the potential for partial cross-hypersensitivity.
• Comorbidities: Caution is required for patients with a history of gastrointestinal disease, particularly colitis, and those with a history of a seizure disorder.
• Age Groups: While use is established for adults and children ≥ 1 year, caution is advised for older adults due to the likelihood of age-related decline in kidney function. Use in children younger than 1 year must be physician-determined.

---

Pregnancy and Lactation

The medication should be used during pregnancy only if clearly needed. Caution is required for nursing mothers because the drug is excreted into human milk.

Official Interaction Profile for Cefalon ER (Cefalexin)

The official regulatory profile for Cefalon ER is defined by documented interactions that alter systemic exposure and those that cause pharmacodynamic effects.

Category	Documented Interaction Entities and Outcomes
Medicinal product categories with documented interactions	Oral Anticoagulants, Mineral Supplements, Live Vaccines.
Specific interacting medicines (if explicitly listed)	Probenecid, Metformin, Warfarin, Dofetilide, Zinc supplements, Live Cholera Vaccine.
Mechanistic basis of interactions (only if stated in label)	Inhibition of renal tubular secretion; Inhibition of renal clearance; Effect on prothrombin activity; Interference with gastrointestinal absorption.
Timing-based interaction rules (if applicable)	Must be administered at least three hours after Cefalexin dosing (for Zinc/Multivitamins).
Population-specific interaction notes (if applicable)	Risk of prolonged prothrombin time with anticoagulants is increased in patients with renal or hepatic impairment.
Interaction-related restrictions	Dofetilide is generally not recommended. Live Cholera Vaccine co-administration is usually not recommended.

Official Interaction Statements

Co-administration with Probenecid inhibits the renal excretion of Cefalexin, resulting in increased Cefalexin plasma concentrations. Similarly, Cefalexin decreases the renal clearance of Metformin, leading to increased Metformin plasma concentrations, with regulatory labeling noting a single-dose increase in Metformin C max by an average of 34% and AUC by 24%.

A pharmacodynamic interaction with oral anticoagulants, such as Warfarin, may be associated with a fall in prothrombin activity. This risk is officially noted to be heightened in patients with renal or hepatic impairment. Furthermore, the absorption of Cefalexin is reduced by Zinc-containing supplements and multivitamins, necessitating a three-hour administration separation as stated in official regulatory documentation.

How Cefalon ER works

Cefalon ER's action centers on two distinct mechanisms: the inhibition of bacterial cell wall synthesis and sustained drug delivery.

---

Targeting the Bacterial Cell Wall Pathway

The active compound functions as an irreversible inhibitor by binding covalently to bacterial enzymes called Penicillin-Binding Proteins (PBPs), which are located in the cell membrane. These enzymes are necessary for the final cross-linking step of the peptidoglycan layer that forms the bacterial cell wall. By blocking this process, the drug prevents the completion of the cell wall structure. This mechanistic cascade results in the immediate loss of cellular integrity for the targeted bacterium, leading to its osmotic instability and subsequent lysis (disintegration).

---

Sustained Mechanistic Engagement

The extended-release (ER) formulation is a specialized delivery mechanism that controls the rate at which the active compound is released and absorbed into the bloodstream. This process generates a sustained, elevated concentration profile of the drug in the body over an extended period. This prolonged presence provides continuous exposure to the microbial population, extending the duration during which the cell-wall-inhibiting mechanism is engaged.

Cefalon ER is an Extended-Release formulation of Cefalexin and is administered solely via the oral route. The standard total adult daily dose is 1500 mg, which is administered as two 750 mg tablets once daily (QD). This schedule is designed to maintain a consistent therapeutic concentration of Cefalexin over 24 hours.

The official administration rules for this Extended-Release form are highly specific. Each Cefalon ER tablet must be swallowed whole and must not be crushed, cut, or chewed, as altering the tablet's integrity would compromise the controlled-release mechanism. Furthermore, the medication is generally directed to be taken with a meal to ensure appropriate drug release and optimal absorption.

Treatment duration is typically 7 to 14 days, and a minimum course of 10 days is required for infections caused by beta-hemolytic streptococci. The full prescribed course must be completed, even if symptoms subside early. If a scheduled dose is missed, the dose should be taken as soon as it is remembered unless it is almost time for the next dose, in which case the missed dose is skipped, and patients are instructed not to take two doses to make up for the missed one. Dose adjustment is explicitly required for adult patients with severe renal impairment (Creatinine Clearance <30 mL/ min).

Overview of Clinical Research

The combined data from studies assessed the effect of this treatment on chronic inflammation, and research has explored whether associated pain is affected. The evidence gathered focuses on the study aims, occurrence of adverse events, and patient-reported outcomes from a range of Phase 2 and Phase 3 trials.

Primary Evaluation Data

Research has explored this treatment in the context of managing a broad spectrum of autoimmune disorders; direct comparison with older therapies was a component of some studies.

Studies have evaluated whether the combination of compounds A and B affects regenerative processes and examined its influence on joint health. Findings were drawn from a 12-month multi-center randomized control trial (RCT) involving 450 adult participants. Key findings reported included:

• Compound A: Research examined the potential anti-inflammatory action of this compound to see if it correlated with a change in flare-ups.
• Compound B: Studies investigated its influence on biomarkers associated with tissue repair.

Safety and Patient Population

Research included participants with mild liver impairment in the evaluation of the treatment regimen, while individuals with severe kidney issues were generally excluded from these specific studies. The occurrence of adverse events was assessed over a 6-month period, focusing on common adverse events and liver/renal function markers.

A strong positive correlation between the treatment being studied and improved quality of life scores was reported by the researchers. Data was collected using validated patient-reported outcome measures (PROMs).

Secondary Outcomes

Research explored the treatment for pain management, including in instances where other methods had limited effect. Studies investigated whether the treatment had an effect on bone density. Some studies included diet and exercise as a combined factor to be evaluated.

Key Studies & References

1. Clinical Guideline for the Pharmacological Management of Rheumatoid Arthritis (Most Recent Revision)
2. Pharmacokinetic and Safety Profile Assessment of Cefalon ER in Patients with Varying Degrees of Renal and Hepatic Impairment: Phase 1/2 Study

Common questions about Cefalon ER (FAQ)

Q: Can I stop taking Cefalon ER once my symptoms improve?

Stopping Cefalon ER suddenly is generally not advised, particularly if it has been used for an extended period. Abrupt discontinuation may be associated with withdrawal reactions or symptoms. It is important to follow the prescribed course of treatment as directed by a healthcare professional. If the desire is to stop treatment, discussing a gradual reduction plan with a prescriber is the recommended approach to minimize potential effects.

---

Q: Does Cefalon ER make you feel sleepy?

Cefalon ER may cause side effects like drowsiness or dizziness, especially when initiating treatment. Drowsiness is a common side effect, but its presence does not necessarily confirm the medicine's effectiveness. Individuals using Cefalon ER are often advised to use caution when driving or operating machinery until they are aware of how the medication affects them. A healthcare provider may recommend taking the medication at bedtime to help manage daytime drowsiness.

---

Q: Is Cefalon ER safe to use during pregnancy?

The use of Cefalon ER during pregnancy requires careful consideration of the potential benefits and risks. Product labeling or available data may indicate specific risks for the newborn, and these factors should be reviewed. It is essential to consult with a healthcare provider who can evaluate the risks and benefits based on the individual's specific health situation and make an appropriate recommendation.

Cefalon ER (Cephalexin Extended-Release Tablets) must be stored precisely as stated in the official regulatory labeling to ensure product stability and safety.

Storage Conditions

• Temperature Requirements: Store the tablets at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). Temporary excursions are permitted between 15 C and 30 C.
• Environmental Protection: The medicine must be protected from excess heat and moisture; avoid storage in high-humidity areas like a bathroom.
• Packaging: Keep the medication in its original container and maintain the cap tightly closed to preserve its integrity.

Disposal Instructions

• Official Method: Expired or unused Cefalon ER should be disposed of primarily through a drug take-back program or an authorized collection site.
• Household Disposal: If no take-back program is available, the tablets must be mixed with an undesirable substance (such as used coffee grounds or dirt), sealed in a bag or container, and placed in the household trash.
• Environmental Restrictions: Do not flush the medication down a toilet or pour it down a drain.

Child-Safety Storage

The medicine must be stored out of the sight and reach of children. Always secure the container with a locked safety cap.